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Abstract
The aim of this project was to cross-culturally adapt and validate the Juvenile Arthritis Multidimensional Assessment 
Report (JAMAR) questionnaire in 54 languages across 52 different countries that are members of the Paediatric Rheu-
matology International Trials Organisation (PRINTO). This effort was part of a wider project named Epidemiology and 
Outcome of Children with Arthritis (EPOCA) to obtain information on the frequency of juvenile idiopathic arthritis 
(JIA) categories in different geographic areas, the therapeutic approaches adopted, and the disease status of children with 
JIA currently followed worldwide. A total of 13,843 subjects were enrolled from the 49 countries that took part both in 
the cross-cultural adaptation phase and in the related validation and data collection: Algeria, Argentina, Belgium, Bra-
zil, Bulgaria, Canada, Chile, Colombia, Croatia, Czech Republic, Denmark, Ecuador, Egypt, Estonia, Finland, France, 
Georgia, Germany, Greece, Hungary, India, Islamic Republic of Iran, Israel, Italy, Latvia, Libya, Lithuania, Mexico, 
Netherlands, Norway, Oman, Paraguay, Poland, Portugal, Romania, Russian Federation, Saudi Arabia, Serbia, Slovakia, 
Slovenia, South Africa, Spain, Sweden, Switzerland, Thailand, Turkey, Ukraine, United Kingdom and United States of 
America. 9021 patients had JIA (10.7% systemic arthritis, 41.9% oligoarthritis, 23.5% RF negative polyarthritis, 4.2% 
RF positive polyarthritis, 3.4% psoriatic arthritis, 10.6% enthesitis-related arthritis and 5.7% undifferentiated arthritis) 
while 4822 were healthy children. This introductory paper describes the overall methodology; results pertaining to each 
country are fully described in the accompanying manuscripts. In conclusion, the JAMAR translations were found to 
have satisfactory psychometric properties and it is thus a reliable and valid tool for the multidimensional assessment 
of children with JIA.
Keywords Juvenile Arthritis Multidimensional Assessment Report (JAMAR) · Cross-cultural adaptation and psychometric 
evaluation methodology · Juvenile idiopathic arthritis (JIA) · Healthy children · Review
Introduction
In recent years, there has been an increasing interest in 
parent/patient-reported outcomes (PROs) in juvenile idi-
opathic arthritis (JIA). Inclusion of these measures in 
patient assessment is deemed important as they reflect the 
parents’ and children’s perception of the disease course 
and effectiveness of therapeutic interventions. It has been 
suggested that PROs should be incorporated into routine 
paediatric rheumatology care. A number of measures for 
the assessment of PROs in children with JIA have been 
developed over the years, including questionnaires for the 
evaluation of functional ability and health-related quality 
of life (HRQoL), and visual analogue scales for parent/
patient rating of well-being and pain [1]. However, most 
of these measures have remained essentially research tools 
and are not routinely administered in most paediatric rheu-
matology centres.
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A multidimensional questionnaire was developed for the 
assessment of children with JIA in standard clinical care, 
which incorporates the traditional PROs (functional abil-
ity, HRQoL, overall well-being, pain) and other PROs such 
as morning stiffness, rating of disease course over time, 
proxy- or self-assessment of joint involvement, description 
of side effects of medications, and assessment of therapeutic 
compliance and satisfaction with the outcome of the illness. 
Administration of this questionnaire can provide physicians 
with a thorough and systematic overview of the patient sta-
tus to be scanned at the start of the visit either on paper or 
online tools in the currently ongoing PRINTO academic pro-
jects. This facilitates focus on matters that require attention, 
leading to more efficient and effective clinical care. This 
tool is named Juvenile Arthritis Multidimensional Assess-
ment Report (JAMAR) [2]. A parent proxy-report version, a 
child and adult self-report version of the JAMAR is available 
for use either on paper or on electronic devices. While the 
parent proxy-report and the child versions are fully cross-
culturally adapted in several languages and validated as part 
of this supplement, the adult versions, which required modi-
fication in just few words, have been only cross-culturally 
adapted to accommodate participants as they matured into 
young adulthood. In the Istituto Giannina Gaslini clinic 
and in other paediatric wards where it is routinely used for 
the on-going PRINTO academic projects, the JAMAR has 
been found very user-friendly, easy to understand, and read-
ily responded by parents and patients. It is quick, taking 
5–10 min to complete and can be scanned by a health profes-
sional for a clinical overview in a few seconds, especially the 
electronic version, which summarises in few lines the most 
relevant findings either to health professionals and fami-
lies/patients. Some components of the JAMAR have been 
already published in separate papers [3–5].
The widespread membership of the Paediatric Rheuma-
tology International Trials Organisation (PRINTO at https 
://www.print o.it with more than 60 countries) [6] and the 
growing international collaboration along with the growing 
numbers of foreign patients requires the availability of the 
JAMAR cross-culturally adapted and validated according to 
international guidelines [7].
The aim of the present manuscript is to report the overall 
methodology for the cross-cultural adaptation and validation 
of the JAMAR into the languages of the countries belong-
ing to PRINTO that agreed to be part of this international 
initiative.
Methods
Patients
Centres belonging to PRINTO were invited to participate. 
The validation of the JAMAR is part of a wider project 
named EPidemiology, treatment and Outcome of Child-
hood Arthritis (EPOCA) [8], which has the goal to obtain 
information on the frequency of JIA subtypes in different 
geographic areas, the therapeutic approaches followed 
by paediatric rheumatologists from diverse countries or 
continents, and the current disease and health status of 
children with JIA followed worldwide. Additional objec-
tives are to investigate the availability of biologic medi-
cations in different countries to foster the regular use of 
standardized quantitative clinical measures in the clini-
cal assessment of children with JIA in standard clinical 
care, and to promote the embracement of a uniform set of 
outcome measures across international paediatric rheu-
matology centres [8]. In brief, the National Coordinators 
of PRINTO (list at https ://www.print o.it) were asked to 
coordinate the translation procedures (see below). To 
ensure that the data regarding the epidemiology, treat-
ment and outcome of JIA are reliable, the collection of 
a representative sample of the patients followed at each 
participating centre was planned. Additionally, each 
centre was asked to enrol 100 unselected and possibly 
consecutive patients meeting the International League of 
Associations for Rheumatology (ILAR) criteria for JIA 
or, if the centre did not expect to see at least 100 patients 
within 6 months, to enrol all consecutive and unselected 
patients meeting the same criteria seen within the first 
6 months after the study start.
The protocol was approved by the institutional ethics 
committees of the participating paediatric rheumatology 
centres as required by the national laws of each country. 
Parents/guardians/patients provided written informed con-
sent to participate in the study.
Standard forms for data collection were designed using 
consensus methodologies at the PRINTO international 
Coordinating Centre in Genoa, Italy.
Patients with all JIA categories according to the ILAR 
criteria [9] were included in the study. All patients under-
went clinical, rheumatologic, laboratory assessments and 
completed the JAMAR to evaluate the current status, 
including
• the physician’s evaluation of current disease activity on 
a 21-circle visual analogue scale (VAS);
• the parental assessment of overall well-being on a 
21-circle VAS;
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• the number of joints with active arthritis;
• the number of joints with swelling, pain, and limited 
range of motion;
• the C-reactive protein (CRP) and the erythrocyte sedi-
mentation rate (ESR) (Westergren method).
Healthy controls were recruited from local schools 
(children from 6 to 18 years of age) and among the healthy 
brother(s) and sister(s) of the JIA children attending the 
clinics. A child was defined as healthy after examination 
by a physician and/or based on the parent’s declaration. 
Healthy controls completed just the JAMAR.
The questionnaires
A parent or legal guardian of each patient seen at the 
study units from October 2010 to August 2017 who was 
< 18 years was asked to complete the parent version of 
the JAMAR at each visit. On the same occasion, the child 
was asked to complete independently the patient version 
of the JAMAR. Methodology for the JAMAR development 
followed the FDA conceptual framework for developing 
a PRO instrument [10] and has been previously reported 
[2–5].
The JAMAR [2] includes the following 15 sections:
 1. Assessment of physical function (PF) using 15 items 
in which the ability of the child to perform each task 
is scored as follows: 0 = without difficulty, 1 = with 
some difficulty, 2 = with much difficulty, 3 = unable 
to do. If it was not possible to answer the question or 
the child was unable to perform the task due to their 
young age or to reasons other than JIA the score was: 
not applicable. The total PF score ranges from 0 to 45 
and has three components: PF-lower limbs (PF-LL); 
PF-hand and wrist (PF-HW) and PF-upper segment 
(PF-US) each scoring from 0 to 15 [3]. Higher scores 
indicate higher degree of disability [11–13]
 2. Rating of the intensity of the patient’s pain on a 
21-numbered circle visual analogue scale (VAS) 
(0 = no pain; 10 = very severe pain) [4];
 3. assessment of the presence of joint pain or swelling 
in the following joints or joint groups: cervical spine, 
lumbosacral spine, shoulders, elbows, wrists, small 
hand joints, hips, knees, ankles, and small foot joints 
(present/absent for each joint);
 4. assessment of morning stiffness (present/absent) and 
duration of morning stiffness;
 5. assessment of extra-articular symptoms (fever and 
rash) (present/absent);
 6. rating of the level of disease activity on a 21-circle 
VAS (0 = no activity; 10 = maximum activity) [4]. 
Although the ability of parents/patients to under-
stand the meaning and to be able to report the extent 
of disease activity may be questionable, we decided 
to include this VAS to investigate whether it could 
be a better indicator of the level of disease activity 
than the well-being VAS. The latter scale has been 
found to reflect the effects of both disease process 
and damage, particularly in patients with long-last-
ing disease [4];
 7. rating of disease status at the time of the visit (remis-
sion, continued activity or relapse);
 8. rating of disease course from previous visit (much 
improved, slightly improved, stable, slightly worsened 
or much worsened);
 9. checklist of the medications the patient is taking (list 
of choices);
 10. checklist of side effects of medications;
 11. report of difficulties with medication administration 
(list of items);
 12. report of school/university/work problems caused by 
the disease (list of items);
 13. assessment of HRQoL using a ten-item scale through 
the Physical Health (PhH), and Psychosocial Health 
(PsH) subscales (five items each) and a total score. The 
four-point Likert response, referring to the prior month, 
is ‘never’ (score = 0), ‘sometimes’ (score = 1), ‘most 
of the time’ (score = 2) and ‘all the time’ (score = 3). 
A ‘not applicable column was included in the parent 
version of the questionnaire to designate questions 
that could not be answered because of developmental 
immaturity. The total HRQoL score ranges from 0 to 
30, with higher scores indicating worse HRQoL. A 
separate score for PhH and PsH (range 0–15) can be 
calculated [14–16]
 14. rating of the patient’s overall well-being on a 21-num-
bered circle VAS;
 15. a question about satisfaction with the outcome of the 
illness (Yes/No) [17].
The JAMAR is available in three versions, one for parent 
proxy-report (child’s age 2–18), one for child self-report, 
with the suggested age range of 7–18 years, and one for 
adult patients.
Outline of the methods
The PRINTO project was divided into two phases (Fig. 1): 
phase I, the cross-cultural adaptation, which involved the 
translation procedures and preliminary probe in the target 
population; and phase II, the validation, which consisted of 
large scale data collection for psychometric and statistical 
evaluation.
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Phase I: cross-cultural adaptation
The process of cross-cultural adaptation followed the guide-
lines provided by Guillemin et al. [18].
To facilitate comparisons among the different languages, 
the three versions of the questionnaire were, respectively, 
divided as follows: 123 lines of translations for the parent 
version of JAMAR and 120 lines of translations for child/
adult version of JAMAR.
Forward translations into national languages At least two 
(preferably three) literal translations from English have been 
done by 2–3 independent translators into their native lan-
guage. The 2–3 translators were fluent in English and in the 
local language, were of different educational levels, back-
ground and sex, were instructed to use wording that could 
be understood by a 8–10-year old child (for the patient ver-
sion of the JAMAR), and at least one of them was unaware 
of the purpose of the translations (e.g. should not be health 
professionals).
First unified forward translation The 2–3 forward transla-
tors and 1 or 2 other persons not involved in the translation 
procedures (e.g. the local principal investigator and a nurse/
physical therapist), met each other to reach a consensus (that 
was to reconcile differences in the forward translations) 
among the members of the group to obtain a first unified 
version from the 2–3 forward translations.
Backward translations into  English The first unified ver-
sion of the questionnaires was back-translated by at least 
two (preferably three) independent backward translators 
with English as their first language and familiar with the 
idioms and colloquial form of the source national language. 
The 2–3 backward translators must not have taken part in 
the previous step. Backward translation is aimed at improv-
Fig. 1  Diagram summaris-
ing the steps followed for the 
cross-cultural adaptation and 
validation procedures
PHASE I: CROSS-CULTURAL ADAPTATION
2 / 3 forward translations
↓
First unified forward version
↓
2 / 3 backward translations
↓
Second unified forward version
↓
Probe technique in the target population
↓
Third unified forward version
Large-scale data collection in healthy and JIA children
↓
Psychometric issues and statistical analysis
↓
Final unified forward version
PHASE II (DATA COLLECTION AND VALIDATION)
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ing the quality of the final version of the questionnaires, by 
pointing out any misunderstandings of the first translation. 
Backward translators were unaware of the purpose of the 
concepts underlying the material and were of different edu-
cational level, background and sex.
Review of backward translations The 2–3 backward trans-
lations were reviewed by PRINTO, whose main task was to 
check their correspondence with the original English ver-
sion.
The aim of this phase was to make sure that the intro-
ductory material and the instructions for the translation of 
the questionnaires were still relevant based upon the final 
version of the translations, that the new translated JAMAR 
was fully comprehensible, and finally to verify its cross-
cultural correspondence with the source text, by compar-
ing their semantic, idiomatic, experiential and conceptual 
equivalencies.
Second unified forward version A second meeting was 
then convened among all the forward and backward trans-
lators to take into account the comments received from the 
review of the backward translations. The purpose of this 
meeting was to reach a consensus among the translators 
for a second unified version of the questionnaires in each 
national language.
Pre-testing in  target population using probe tech-
nique Prior to proceeding to the validation procedure, the 
second unified version of the questionnaire was adminis-
tered to ten parents of patients with JIA and ten children of 
different educational levels and backgrounds, using a probe 
technique to ensure parents’ and children’s understanding 
in the target population. The probe method was carried out 
as follows: a health professional, familiar with the intent of 
each question, administered the questionnaires to the par-
ents and patients, asking to consider each question and elu-
cidate their understanding of each item in an open-ended 
manner. The health professional assessed if the question was 
perfectly understood by each parent and child. Questions 
that were misunderstood by more than 20% of the parents or 
patients were reviewed by the National Coordinating Centre 
and revised appropriately.
Third unified forward version A third meeting was con-
vened among all the forward and backward translators to 
take into account the results of the probe technique. The 
goal of this meeting was to reach a consensus for a final 
unified version of the questionnaires in each language con-
sidered.
In case the JAMAR translation was already available in 
the local language because the first phase of the project was 
already completed in a country with the same official lan-
guage, the PRINTO national coordinator was allowed to test 
only the available version with the probe technique.
Phase II: validation
Following the process of cross-cultural adaptation, a large-
scale data collection phase was set up using the third unified 
forward version of the questionnaires.
Each participating centre was asked to collect demo-
graphic, clinical data and the JAMAR in 100 consecutive 
JIA patients or all consecutive patients seen in a 6-month 
period and to administer the JAMAR to at least 100 healthy 
children and their parents.
The validation procedures followed the classical steps of 
the psychometric theory [19].
Demographic and  clinical characteristics of  the  sub-
jects Descriptive statistics were performed for demo-
graphic and clinical variables. Categorical variables were 
summarized in terms of absolute frequencies and percent-
ages; quantitative variables were reported in terms of medi-
ans and first and third quartiles (1st–3rd q). Comparison of 
quantitative variables between JIA patients and the groups 
of healthy children was made by the Mann–Whitney U 
test due to the ordinal nature of the data. Comparison of 
quantitative scores among the JIA subtypes was made by 
the Kruskal–Wallis test. Correlations were evaluated by 
the Pearson’s correlation coefficient or by the Spearman’s 
correlation coefficient. The correlation coefficients were 
classified as follows: r < 0.4 = weak, 0.4–0.59 = moderate, 
0.6–0.79 = strong and ≥ 0.80 = very strong correlation [20]. 
All statistical tests were two-sided and a P value < 0.05 was 
considered as statistically significant.
Descriptive analysis of the items The median and first and 
third quartiles of missing values and items marked as not 
applicable for each item have been calculated. The pattern 
of responses has been also evaluated to determine whether 
the data will be normally or skewed distributed (e.g. do peo-
ple report at either extremes of the response continuum?). 
The means and standard deviations of items within a scale 
should be roughly equivalent (first Likert assumption); if 
this assumption is met, then it is possible to avoid a weight-
ing of the items.
Floor and ceiling effects have been performed to check 
whether scale scores have substantial variability in the popu-
lation of interest. The floor effect refers to the frequency 
of the lowest possible responses within an item, while the 
ceiling effect refers to the frequency of the highest possible 
responses within an item.
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Equal item-scale correlation (second Likert assump-
tion) These should be roughly equivalent for items within a 
scale when corrected for overlap. This analysis will be car-
ried out using the Pearson correlation coefficients to test the 
second Likert assumption (equal item–scale correlations); 
that is, each item should contribute roughly an equal propor-
tion of information to the total score regarding the construct 
being measured. If the items have roughly equal variances, 
they do not need to be standardized.
Item internal consistency (item–scale correlation corrected 
for overlap) It tests the third Likert assumption, e.g. items 
should be substantially linear related to the total score com-
puted from the items in that scale. It requires a Pearson item 
correlation of at least 0.4 after correction for item–scale 
overlap. Items not meeting these criteria might have to be 
revised. It is considered satisfactory if 90% or more of the 
items meet these criteria.
Internal consistency (Cronbach’s alpha) It refers to the 
extent to which the measured variance in a score reflects 
the true score rather than random error; that is, the extent 
to which measures give consistent or accurate results. Reli-
ability was measured by Cronbach’s alpha coefficients that 
is considered acceptable if ≥ 0.7 [21]. Therefore, the items 
should all measure the same latent construct, and this coef-
ficient gives a measure of the internal consistency; these 
coefficients were calculated either for subscales or for the 
entire questionnaire.
Interscale correlation It was tested using the means of 
Pearson correlation coefficients. It requires that the cor-
relation between two scales is less than their reliability 
coefficients as measured by Cronbach’s alpha. It can be 
viewed as a correlation between a scale and itself, and it 
is used to evaluate how each scale is distinct from other 
scales [22].
Test–retest reliability It is a test of stability and represents 
the reproducibility within the same individual 1–2  weeks 
apart from the first administration of the questionnaire. The 
intra-class correlation coefficient (ICC) was classified as 
follows: ICC < 0.2 = poor, 0.2–0.39 = fair, 0.4–0.59 = mod-
erate, 0.6–0.79 = substantial and ≥ 0.80 = almost perfect 
reproducibility [21].
Convergent validity It is the correlation of the summary 
scores with external criterion variables not used to score the 
scales. This was done by assessing the Spearman correla-
tion coefficients of the PF total score, the PhS and PsS sub-
scales of the HRQoL section and the 21-circle VAS for pain, 
disease activity, and well-being with the other variables 
included in the core set variables for JIA, that are the physi-
cian’s evaluation of current disease activity, the number of 
joints with active arthritis, the number of joints with limited 
range of motion, and the ESR [23]. Correlations of PF and 
HRQoL scores with the VAS included in the JAMAR were 
also assessed.
Software All data were analysed using SAS 9.3 (Institute 
Inc., Cary, NC, USA) software.
Results
A total of 13,843 subjects were enrolled from 49 countries: 
Algeria, Argentina, Belgium, Brazil, Bulgaria, Canada, 
Chile, Colombia, Croatia, Czech Republic, Denmark, Ecua-
dor, Egypt, Estonia, Finland, France, Georgia, Germany, 
Greece, Hungary, India, Islamic Republic of Iran, Israel, 
Italy, Latvia, Libya, Lithuania, Mexico, Netherlands, Nor-
way, Oman, Paraguay, Poland, Portugal, Romania, Russian 
Federation, Saudi Arabia, Serbia, Slovakia, Slovenia, South 
Africa, Spain, Sweden, Switzerland, Thailand, Turkey, 
Ukraine, United Kingdom and United States of America. 
As shown in Table 1 9021 patients had JIA (10.7% with 
systemic arthritis, 41.9% with oligoarthritis, 23.5% with RF 
negative polyarthritis, 4.2% with RF positive polyarthritis, 
3.4% with psoriatic arthritis, 10.6% with enthesitis-related 
arthritis and 5.7% with undifferentiated arthritis) while 4822 
were healthy children.
In Table  2 is reported the list of PRINTO National 
Coordinators who oversaw the cross-cultural adaptation 
phase and the data collection for the validation phase in the 
respective countries, while in Table 3 is reported the list of 
PRINTO Directors who oversaw the data collection for the 
validation phase in their respective centres.
JAMAR cross‑cultural adaptation
The current supplement contains the cross-cultural adapta-
tion and validation of the JAMAR for the 49 countries listed 
above (see Table 1).
Two forward and two backward translations were car-
ried out for 22 countries: Argentina, Chile, Croatia, Czech 
Republic, Denmark, Egypt, Estonia, Georgia, Germany, 
Iran, Israel, Latvia, Lithuania, Netherlands, Norway, Roma-
nia, Slovakia, South Africa, Sweden, Switzerland, Thailand 
and Ukraine. For Greece, two forward translations and three 
backward translations were available. Three forward and two 
backward translations were obtained for 14 countries: Bra-
zil, Bulgaria, Finland, France, India, Italy, Mexico, Poland, 
Portugal, Russian Federation, Saudi Arabia, Serbia, Slovenia 
and Turkey. For Hungary and Spain, three forward and three 
backward translations were done.
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Table 1  Number of patients with JIA (frequency in brackets) and number of healthy children collected in the 49 countries participating in Phase 
I (cross-cultural adaptation) and Phase II (data collection and validation)
Countries Systemic Oligoarthritis RF − polyarthritis RF + polyar- 
thritis
Psoriatic  
arthritis
Enthesitis- 
related arthritis
Undifferentiated 
arthritis
All JIA patients Healthy
Algeria 7 (10%) 25 (36%) 15 (21%) 14 (20%) 1 (1%) 8 (12%) 0 (0%) 70 70
Argentina 86 (23%) 115 (31%) 105 (28%) 37 (10%) 5 (1%) 23 (6%) 2 (1%) 373 100
Belgium 8 (8%) 33 (33%) 24 (24%) 2 (2%) 6 (6%) 13 (13%) 14 (14%) 100 99
Brazil 34 (15%) 100 (43%) 52 (22%) 11 (5%) 4 (2%) 25 (11%) 5 (2%) 231 72
Bulgaria 22 (12%) 98 (53%) 43 (23%) 3 (2%) 3 (2%) 9 (5%) 5 (3%) 183 100
Canada 6 (3%) 87 (41%) 58 (28%) 6 (3%) 9 (4%) 22 (11%) 20 (10%) 208 152
Chile 6 (12%) 12 (25%) 11 (22%) 1 (2%) 0 (0%) 4 (8%) 15 (31%) 49 70
Colombia 2 (9%) 3 (14%) 6 (27%) 3 (14%) 0 (0%) 8 (36%) 0 (0%) 22 0
Croatia 7 (7%) 38 (38%) 19 (19%) 5 (5%) 0 (0%) 12 (12%) 19 (19%) 100 100
Czech Republic 6 (6%) 37 (36%) 39 (38%) 1 (1%) 3 (3%) 13 (12%) 4 (4%) 103 100
Denmark 24 (8%) 106 (35%) 67 (22%) 17 (6%) 19 (6%) 39 (13%) 31 (10%) 303 99
Ecuador 4 (17%) 1 (4%) 4 (17%) 4 (17%) 0 (0%) 2 (9%) 8 (36%) 23 23
Egypt 20 (20%) 10 (10%) 24 (24%) 2 (2%) 2 (2%) 2 (2%) 40 (40%) 100 100
Estonia 0 (0%) 79 (72%) 20 (18%) 2 (2%) 2 (2%) 2 (2%) 5 (4%) 110 98
Finland 2 (1%) 80 (46%) 69 (40%) 1 (1%) 1 (1%) 13 (7%) 7 (4%) 173 100
France 23 (23%) 45 (45%) 20 (20%) 3 (3%) 0 (0%) 5 (5%) 4 (4%) 100 122
Georgia 26 (26%) 57 (57%) 16 (16%) 1 (1%) 0 (0%) 0 (0%) 0 (0%) 100 100
Germany 9 (3%) 117 (37%) 75 (23%) 10 (3%) 18 (6%) 65 (20%) 25 (8%) 319 100
Greece 16 (6%) 157 (57%) 58 (21%) 1 (1%) 8 (3%) 16 (6%) 16 (6%) 272 100
Hungary 8 (4%) 85 (41%) 58 (28%) 4 (2%) 10 (5%) 33 (16%) 8 (4%) 206 90
India 78 (28%) 30 (11%) 38 (14%) 19 (7%) 5 (2%) 88 (32%) 17 (6%) 275 98
Iran 15 (15%) 69 (67%) 16 (16%) 1 (1%) 1 (1%) 0 (0%) 0 (0%) 102 198
Israel 20 (17%) 65 (56%) 24 (20%) 1 (1%) 2 (2%) 3 (3%) 1 (1%) 116 98
Italy 93 (7%) 772 (60%) 277 (21%) 18 (1%) 49 (4%) 45 (4%) 42 (3%) 1296 100
Latvia 2 (2%) 56 (56%) 17 (17%) 13 (13%) 4 (4%) 7 (7%) 1 (1%) 100 204
Libya 22 (22%) 26 (26%) 25 (25%) 5 (5%) 4 (4%) 13 (13%) 5 (5%) 100 100
Lithuania 6 (6%) 39 (38%) 24 (24%) 1 (1%) 15 (15%) 15 (15%) 1 (1%) 101 116
Mexico 16 (16%) 16 (16%) 20 (20%) 30 (30%) 1 (1%) 16 (16%) 1 (1%) 100 99
Netherlands 30 (14%) 83 (40%) 54 (26%) 9 (4%) 9 (4%) 12 (6%) 12 (6%) 209 107
Norway 10 (3%) 124 (41%) 78 (26%) 10 (3%) 12 (4%) 27 (10%) 40 (13%) 301 74
Oman 13 (23%) 16 (28%) 20 (35%) 6 (10%) 2 (4%) 0 (0%) 0 (0%) 57 85
Paraguay 1 (2%) 14 (27%) 19 (37%) 9 (18%) 3 (6%) 5 (10%) 0 (0%) 51 100
Poland 16 (10%) 77 (50%) 38 (25%) 9 (6%) 0 (0%) 8 (5%) 6 (4%) 154 91
Portugal 5 (6%) 55 (69%) 3 (4%) 3 (4%) 0 (0%) 11 (13%) 3 (4%) 80 30
Romania 37 (12%) 67 (22%) 99 (32%) 29 (9%) 6 (2%) 62 (20%) 10 (3%) 310 100
Russian Federation 25 (25%) 19 (19%) 38 (38%) 3 (3%) 0 (0%) 15 (15%) 0 (0%) 100 198
Saudi Arabia 27 (27%) 23 (23%) 25 (25%) 13 (13%) 6 (6%) 3 (3%) 3 (3%) 100 100
Serbia 13 (5%) 110 (44%) 59 (24%) 11 (4%) 6 (3%) 39 (16%) 10 (4%) 248 100
Slovakia 6 (6%) 42 (39%) 33 (30%) 4 (4%) 0 (0%) 14 (13%) 9 (8%) 108 100
Slovenia 7 (7%) 47 (47%) 22 (22%) 2 (2%) 4 (4%) 9 (9%) 9 (9%) 100 120
South Africa 4 (4%) 32 (35%) 21 (23%) 6 (7%) 6 (7%) 14 (15%) 8 (9%) 91 98
Spain 45 (9%) 260 (49%) 96 (18%) 5 (1%) 29 (5%) 50 (10%) 41 (8%) 526 78
Sweden 6 (9%) 30 (44%) 9 (13%) 2 (3%) 3 (4%) 8 (12%) 10 (15%) 68 76
Switzerland 3 (3%) 43 (44%) 16 (16%) 0 (0%) 2 (2%) 25 (26%) 9 (9%) 98 64
Thailand 47 (45%) 11 (11%) 10 (9%) 11 (11%) 0 (0%) 25 (24%) 0 (0%) 104 102
Turkey 64 (14%) 189 (41%) 105 (22%) 11 (2%) 15 (3%) 70 (15%) 12 (3%) 466 93
Ukraine 12 (12%) 44 (44%) 20 (20%) 3 (3%) 1 (1%) 16 (16%) 4 (4%) 100 100
United Kingdom 7 (7%) 38 (38%) 27 (27%) 1 (1%) 5 (5%) 9 (9%) 13 (13%) 100 100
USA 16 (5%) 98 (31%) 107 (34%) 16 (5%) 28 (9%) 34 (11%) 16 (5%) 315 98
Total (N = 49  
countries)*
962 3780 2123 379 309 957 511 9021 4822
*Additional 3 countries (Albania, Costa Rica and Peru) participated only in Phase I (cross-cultural adapation)
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Table 2  List of the 54 country-specific principle investigators (51 PRINTO National Coordinators and 3 representatives for Canada and USA) 
who oversaw the Phase I (cross-cultural adaptation) and the Phase II (data collection and validation) in their respective countries
First name Last name Institution Town Country
Anuela Kondi University Hospital Centre Tirana Albania
Maya-Feriel Aiche Établissement Hospitalier Spécialisé (EHS Douera), Department 
of Rheumatology
Alger Algeria
Stella Maris Garay Hospital Sor María Ludovica La Plata Argentina
Dehoorne Joke Gent University Hospital Gent Belgium
Claudia Saad Magalhaes Hospital das Clínicas - Botucatu Medicine University, UNESP Botucatu Brazil
Dimitrina Mihaylova University Children Hospital Sofia Bulgaria
Paivi Miettunen Alberta Children’s Hospital Calgary Canada
Gaelle Chédeville The Montreal Children’s Hospital Montreal Canada
Ximena Norambuena Hospital Dr. Exequiel Gonzalez Cortes Santiago Chile
Clara Malagon Hospital Universitario Simon Bolivar Bogota Colombia
Olga Arguedas Hospital Nacional De Ninos Dr. Carlos Saenz Herrera San Jose Costa Rica
Miroslav Harjacek Clinical Hospital Center Sestre Milosrdnice Zagreb Croatia
Pavla Dolezalova Charles University in Prague and General University Hospital Praha Czech Republic
Susan Nielsen Rigshospitalet Copenhagen Denmark
Cristina Herrera Mora Hospital de Niños Roberto Gilbert Elizalde Guayaquil Ecuador
Yasser El Miedany Ain Shams University Cairo Egypt
Chris Pruunsild Tartu University Hospital, Children’s Clinic Tartu Estonia
Pekka Lahdenne Children’s Hospital, Helsinki University Central Hospital Helsinki Finland
Pierre Quartier Paris-Descartes University, IMAGINE Institute, Necker Chil-
dren’s Hospital
Paris France
Maka Ioseliani M. Iashvili Children’s Central Clinic Tbilisi Georgia
Dirk Foell University Hospital Muenster Muenster Germany
Maria Trachana Hippokration General Hospital, Thessaloniki University School 
of Medicine
Thessaloniki Greece
Ilonka Orban National Institute of Rheumatology and Physiotherapy Budapest Hungary
Amita Aggarwal Sanjay Gandhi Postgraduate Institute of Medical Sciences Lucknow India
Nahid Shafaie Shariati Hospital Teheran Islamic Republic of Iran
Yosef Uziel Meir Medical Centre Kfar Saba Israel
Alessandro Consolaro IRCCS Giannina Gaslini Genoa Italy
Ingrida Rumba-Rozenfelde University of Latvia Riga Latvia
Soad Hashad Tripoli Children’s Hospital Tripoli Libya
Violeta Panaviene Vilnius University Vilnius Lithuania
Ruben Burgos-Vargas Hospital General de Mexico Mexico City Mexico
Nico Wulffraat Wilhelmina Kinderziekenhuis Utrecht Netherlands
Berit Flato Oslo University Hospital Oslo Norway
Safiya Al-Abrawi Royal Hospital Muscat Oman
Zoilo Morel Ayala Centro Materno Infantil. Hospital De Clinicas. Universidad 
Nacional De Asuncion
San Lorenzo Paraguay
Amparo Ibanez Estrella National Institute Salud del Nino Breña, Lima Peru
Lidia Rutkowska-Sak Institute of Rheumatology Warsaw Poland
Jose Antonio Melo-Gomes Portuguese Institute of Rheumatology Lisbon Portugal
Calin Lazar Children Emergencies Hospital Cluj-Napoca Romania
Irina Nikishina V.A. Nasonova Research Institute of Rheumatology Moscow Russian Federation
Sulaiman M Al-Mayouf King Faisal Specialist Hospital and Research Center Riyadh Saudi Arabia
Gordana Susic Institute of Rheumatology, Belgrade Belgrade Serbia
Veronika Vargova Faculty of Medicine, Pavol Jozef Šafárik University in Košice Kosice Slovakia
Tadej Avcin University Children’s Hospital, University Medical Centre 
Ljubljana
Ljubljana Slovenia
Christiaan Scott Red Cross Children Hospital and Groote Schuur Hospital Cape Town South Africa
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For some countries with similar languages there was only 
an adaptation of the languages with the changing of words 
whose use is different. This was done for ten countries: Alge-
ria, Libya and Oman from the Saudi Arabia version, Para-
guay from Mexican Spanish version, Flemish from Dutch, 
Ecuadorian Spanish from Argentinian Spanish, Colombian 
Spanish from Castilian Spanish, Swiss German from Ger-
man, Canadian French from Swiss French, American and 
Canadian English from the British English version.
For Albania, Costa Rica (adapting from Castilian Spanish 
version), German-speaking Switzerland (adapting from Ger-
man) and Peru (adapting from Mexican Spanish version), the 
translation phase was completed but the data collection of 
JIA patients and healthy children was not performed.
JAMAR validation
The results of the JAMAR validation pertaining to each 
country are fully described in each of the accompanying 
manuscripts of the supplement.
According to the results of the validation analysis imple-
mented for each participating country, the parent and patient 
versions of the JAMAR possess satisfactory psychometric 
properties. The disease-specific components of the ques-
tionnaire discriminated well between patients with JIA and 
healthy controls. Generally, the results obtained for the par-
ent version of the JAMAR are similar to those obtained for 
the child version, which suggests that children are equally 
reliable proxy reporters of their disease and health status as 
their parents. The JAMAR was found to have satisfactory 
psychometric properties and it is thus a reliable and effec-
tive tool for the multidimensional assessment of children 
with JIA.
Final remarks
The results of the present study show that the cross-cultural 
adaptation is a valid process to obtain reliable instruments 
to be used in the different socio-economic realities of the 
countries participating in the project.
The process of cross-cultural adaptation refers to the 
measurement of the same phenomenon in different cultures 
using the same instruments and should be distinguished 
from the concept of cross-cultural comparison that refers 
to comparative studies of a phenomenon across cultures 
aimed at identifying differences attributable to cultures. 
It was decided to follow the guidelines proposed by Guil-
lemin et al. [18] for the cross-cultural adaptation proce-
dures to have a standardized approach that was easily appli-
cable to all the countries members of PRINTO.
For the countries sharing similar languages, the ques-
tionnaires were adapted from the original mother tongue 
country (i.e. the version for Paraguay, Oman and USA 
were derived from the Mexican Spanish, the Saudi Ara-
bic and the British English versions, respectively); this 
process required merely a change of certain words whose 
use is different in these linguistic varieties. In all the other 
countries, the guidelines proved both easy to apply and 
reliable, with the backward translations revealing that the 
concepts most difficult to render in the target language 
Table 2  (continued)
First name Last name Institution Town Country
Jaime De Inocencio Hospital Universitario 12 de Octubre, and Universidad Com-
plutense de Madrid
Madrid Spain
Boel Andersson Gare Ryhov County Hospital Jonkoping Sweden
Michael Hofer Centre Multisite Romand de Rhumatologie Pediatrique/Centre 
Hospitalier Universitaire Vaudois (CHUV)
Lausanne Switzerland
Traudel Saurenmann Kantonsspital Winterthur Winterthur Switzerland
Soamarat Vilaiyuk Ramathibodi Hospital Bangkok Thailand
Erkan Demirkaya Antalya Life Hospital Antalya Turkey
Yaryna Boyko Western Ukrainian Specialized Children’s Hospital Lviv Ukraine
Neil Martin The Royal Hospital for Children Glasgow United Kingdom
Dan Lovell Cincinnati Children’s Hospital Medical Center Cincinnati, OH United States
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Table 3  List of 60 additional local investigators (58 PRINTO Directors and 2 representatives for USA) who oversaw the Phase II of the project 
(data collection and validation) at their respective centres
First name Last name Institution Town Country
Ruben Cuttica Hospital Pedro de Elizalde Buenos Aires Argentina
Carmen De Cunto Buenos Aires Italy Hospital Buenos Aires Argentina
Graciela Espada Hospital de Ninos Ricardo Gutierrez Buenos Aires Argentina
Maria Martha Katsicas Hospital de Pediatria Juan P. Garrahan Buenos Aires Argentina
Carine Wouters University Hospital Gasthuisberg Leuven Belgium
Sheila K. Oliveira Universidade Federal do Rio de Janeiro Rio de Janeiro Brazil
Flavio Sztajnbok University Hospital Pedro Ernesto Rio de Janeiro Brazil
Boriana Varbanova Varna Medical University Varna Bulgaria
Troels Herlin Skejby Sygehus, Aarhus University Hospital Aarhus Denmark
Anne Estmann Odense University Hospital Odense Denmark
Liisa Kroger Kuopio University Hospital Kuopio Finland
Paula Vahasalo Oulu University Hospital Oulu Finland
Merja Malin Tampere University Hospital Tampere Finland
Anne Putto-Laurila Turku University Hospital Turku Finland
Karaman Pagava Tbilisi State Medical University Pediatric Clinic Tbilisi Georgia
Nikolay Tzaribachev Pediatric Rheumatology Research Institute GmbH Bad Bramstedt Germany
Kirsten Minden Charite University Hospital Berlin Berlin Germany
Hans-Iko Huppertz Clinic Bremen-Mitte, Prof.-Hesse Children’s 
Hospital
Bremen Germany
Johannes-Peter Haas German Center for Pediatric and Adolescent Rheu-
matology
Garmisch-Partenkirchen Germany
Ivan Foeldvari Hamburg Centre for Pediatric and Adolescent 
Rheumatology
Hamburg Germany
Gerd Horneff Asklepios Children’s Hospital Sankt Augustin Sankt Augustin Germany
Gerd Ganser St. Josef-Stift Sendenhorst Sendenhorst Germany
Elena Tsitsami University of Athens Medical School, Children 
Hospital Aghia Sophia
Athens Greece
Olga Vougiouka “P. & A. Kyriakou” Children’s Hospital Athens Greece
Tamas Constantin Semmelweis University Budapest Hungary
Raju Khubchandani Jaslok Hospital and Research Centre Mumbai India
Sujata Sawhney Sir Ganga Ram Hospital Marg New Delhi India
Yahya Aghighi Vali-e-Asr Children’s Hospital Teheran Islamic Republic of Iran
Mohammad Hasan Moradinejad Children’s Hospital, Medical Center Teheran Islamic Republic of Iran
Liora Harel Schneider Childrens Medical Center Petach-Tikvah Israel
Angela Miniaci Azienda Ospedaliero-Universitaria S.Orsola-
Malpighi
Bologna Italy
Francesco La Torre Ospedale Antonio Perrino Brindisi Italy
Rosa Anna Podda Ospedale Regionale Microcitemia—II Clinica 
Pediatrica
Cagliari Italy
Patrizia Barone Catania University Hospital Catania Italy
Elisabetta Cortis Santa Maria della Stella Hospital Ciconia Italy
Rolando Cimaz University Hospital Meyer Firenze Italy
Romina Gallizzi Università di Messina Messina Italy
Fabrizia Corona Fondazione IRCCS Ca’ Granda-Ospedale Mag-
giore Policlinico
Milano Italy
Valeria Gerloni Istituto Gaetano Pini Milano Italy
Maria Cristina Maggio Children Hospital Palermo Italy
Rita Consolini Santa Chiara Hospital, University of Pisa Pisa Italy
Fabrizio De Benedetti Bambino Gesù Children’s Hospital Roma Italy
Donato Rigante Cattolica Sacro Cuore University Roma Italy
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were the categories of answers to the items and the 
instructions statement. For all the other concepts there was 
an excellent concordance between the backward transla-
tions and the original standard English version, indicating 
the reliability of the method.
All translations presented in this supplement have been 
evaluated using traditional multi-trait item scaling analysis.
In conclusion, PRINTO has cross-culturally adapted 
and evaluated the JAMAR in 54 languages across 52 dif-
ferent countries. The JAMAR proved to be a reliable mul-
tidimensional tool for the assessment of patient with JIA. 
Use of well-evaluated translations allows for the standard-
ized assessment of children with JIA.
The manuscripts in this supplement present the prelimi-
nary psychometric findings of the cross-cultural adapta-
tion and psychometric evaluation of the JAMAR for the 49 
countries that took part both in the cross-cultural translation 
phase and in the related data collection.
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Table 3  (continued)
First name Last name Institution Town Country
Silvana Martino Paediatrics, University of Torino Torino Italy
Adele Civino Cardinale G. Panico Hospital Tricase Italy
Serena Pastore IRCCS Burlo Garofolo Trieste Italy
Sara Pieropan G.B. Rossi Verona Italy
Sylvia Kamphuis ErasmusMC Sophia Childrens Hospital Rotterdam Netherlands
Ellen Berit Nordal University Hospital of Northern Norway Tromso Norway
Marite Rygg St. Olavs University Hospital of Trondheim Trondheim Norway
Reem Abdwani Sultan Qaboos University Hospital Muscat Oman
Elzbieta Smolewska Medical University of Łódź Lodz Poland
Adriana Apostol County Emergency Hospital Constanta Romania
Constantin Ailioaie Children Emergencies Hospital Iasi Romania
Matilda Laday County Emergency Hospital Tirgu-Mures Romania
Ekaterina Alexeeva Federal State Autonomous Institution “National 
Medical Research Center of Children’s Health” of 
the Ministry of Health of the Russian Federation
Moscow Russian Federation
Jelena Vojinovic University of Nis, Faculty of Medicine, and Clini-
cal Center Nis
Nis Serbia
Gordana Vijatov-Djuric Institute for Child and Youth Health Care of 
Vojvodina
Novi Sad Serbia
Tomas Dallos Comenius University Medical School Bratislava Slovakia
Jordi Anton Lopez Hospital Sant Joan de Déu, University of Barcelona Barcelona Spain
Alina Lucica Boteanu University Hospital Ramón y Cajal Madrid Spain
Rosa Merino Hospital Universitario La Paz Madrid Spain
Pablo Mesa-del-Castillo Hospital Clínico Universitario Virgen de la Arrix-
aca
Murcia Spain
Inmaculada Calvo Penades University Hospital La Fe Valencia Spain
Lillemor Berntson Uppsala University Hospital Uppsala Sweden
Erbil Unsal Dokuz EyluL University Medical Faculty Balcova, Izmir Turkey
Nuray Aktay Ayaz Kanuni Sultan Süleyman Education and Research 
Hospital
Istanbul Turkey
Ozgur Kasapcopur Istanbul University, Cerrahpasa Medical Faculty Istanbul Turkey
Pamela Weiss Children’s Hospital of Philadelphia Philadelphia, PA United States
Sarah Ringold Seattle Children’s Hospital Seattle, WA United States
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